Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis

被引：33

作者：

van Marion, AMW

Auwerda, JJA

Minnema, MC

van Oosterom, R

Adelmeijer, J

de Groot, PG

Leebeek, FWG

Sonneveld, P

Lokhorst, HM

Lisman, T

机构：

[1] Univ Utrecht, Med Ctr, Dept Haematol G 03 647, Haemostasis & Thrombosis Lab, NL-3584 CX Utrecht, Netherlands

[2] Univ Utrecht, Med Ctr, Dept Pathol, NL-3584 CX Utrecht, Netherlands

[3] Erasmus Med Ctr, Dept Haematol, Rotterdam, Netherlands

[4] Univ Utrecht, Med Ctr, Dept Internal Med, NL-3584 CX Utrecht, Netherlands

来源：

THROMBOSIS AND HAEMOSTASIS | 2005年 / 94卷 / 06期

关键词：

D O I：

10.1055/s-0037-1615590

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1341 / 1343

页数：3

共 14 条

[1] Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma [J].

Carr, ME ;

Dent, RM ;

Carr, SL .

JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1996, 128 (01) :83-88

[2] Acquired activated protein C resistance in myeloma patients with venous thromboembolic events [J].

Deitcher, SR ;

Choueiri, T ;

Srkalovic, G ;

Hussein, MA .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (05) :959-959

[3]

Francis CW, 2002, ARCH PATHOL LAB MED, V126, P1401

[4] Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis [J].

Lisman, T ;

de Groot, PG ;

Meijers, JCM ;

Rosendaal, FR .

BLOOD, 2005, 105 (03) :1102-1105

[5] Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor [J].

Lisman, T ;

Adelmeijer, J ;

Nieuwenhuis, HK ;

de Groot, PG .

BLOOD COAGULATION & FIBRINOLYSIS, 2003, 14 (06) :557-562

[6] Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis [J].

Lisman, T ;

Leebeek, FWG ;

Mosnier, LO ;

Bouma, BN ;

Meijers, JCM ;

Janssen, HLA ;

Nieuwenhuis, HK ;

De Groot, PG .

GASTROENTEROLOGY, 2001, 121 (01) :131-139

[7] Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy [J].

Minnema, MC ;

Breitkreutz, I ;

Auwerda, JJA ;

van der Holt, B ;

Cremer, FW ;

van Marion, AMW ;

Westveer, PHM ;

Sonneveld, P ;

Goldschmidt, H ;

Lokhorst, HM .

LEUKEMIA, 2004, 18 (12) :2044-2046

[8] Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment [J].

Minnema, MC ;

Fijnheer, R ;

De Groot, PG ;

Lokhorst, HM .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (03) :445-449

[9] Deep venous thrombosis and thalidomide therapy for multiple myeloma. [J].

Osman, K ;

Comenzo, R ;

Rajkumar, SV .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) :1951-1952

[10] A CRITICAL-REVIEW OF THE EVIDENCE SUPPORTING A RELATIONSHIP BETWEEN IMPAIRED FIBRINOLYTIC-ACTIVITY AND VENOUS THROMBOEMBOLISM [J].

PRINS, MH ;

HIRSH, J .

ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (09) :1721-1731

← 1 2 →